This proposal seeks to develop and apply a new strategy of cancer therapy through the use of aptamers against target proteins and cells. It focuses on the Basal-like Breast Carcinoma (BLBC), which is a particularly aggressive subtype of breast cancer refractory to conventional therapy. The poor prognosis of BLBC patients is partly due to the lack of estrogen receptor expression and HER2 gene amplification, thus they are not treatable by biologically-based drugs. Using microarray gene expression data and bioinformatic analyses we have identified genes specifically or predominantly expressed in BLBC. Here we choose a subset of these genes as potential drug targets. To determine whether they are indeed responsible for the aggressive behavior of BLBC and therefore can serve as points of intervention, we will create aptamers in the form of stable modified RNA to modulate their activity and to examine the effects of these aptamers on the malignant phenotypes of cancer cells in tissue culture. Moreover, we propose to augment the potency of these target-binding aptamers so that the targets are not only neutralized but also destroyed or damaged. We will develop bi-functional composite aptamers that simultaneously bind the target molecules and the activated complement protein C3b/iC3b, thereby tagging the target molecules and associated cells as """"""""foreign"""""""" in the process of opsonization. Aptamer-mediated opsonization of secreted proteins would lead to their clearance through endocytosis by phagocytes. A salient feature of our approach is that once validated the targets are immediately druggable by the aptamers. The general strategies being developed and principles being uncovered in this project are applicable to other types of cancer.

Public Health Relevance

This study is designed to improve the means of treating a form of aggressive and recalcitrant breast cancer, the Basal-like Breast Carcinoma. The proposed strategy represents a conceptual and technological advance, which transcends the classical pharmacodynamics of antagonism.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA136688-01
Application #
7565007
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Lees, Robert G
Project Start
2009-07-16
Project End
2011-06-30
Budget Start
2009-07-16
Budget End
2010-06-30
Support Year
1
Fiscal Year
2009
Total Cost
$313,475
Indirect Cost
Name
State University of New York at Albany
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
152652822
City
Albany
State
NY
Country
United States
Zip Code
12222
Mallik, Prabhat K; Nishikawa, Kimi; Millis, Albert J T et al. (2010) Commandeering a biological pathway using aptamer-derived molecular adaptors. Nucleic Acids Res 38:e93